These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19823069)

  • 1. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.
    Thuret I; Chaix ML; Tamalet C; Reliquet V; Firtion G; Tricoire J; Rabaud C; Frange P; Aumaître H; Blanche S
    AIDS; 2009 Nov; 23(17):2364-6. PubMed ID: 19823069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
    Vento S; Vallone A
    AIDS Patient Care STDS; 2008 Nov; 22(11):841-2. PubMed ID: 19025477
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
    Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
    AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine.
    Audelin AM; Lebech AM; Petersen AB; Jørgensen LB
    J Med Virol; 2008 Aug; 80(8):1319-21. PubMed ID: 18551616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
    Charpentier C; Roquebert B; Colin C; Taburet AM; Fagard C; Katlama C; Molina JM; Jacomet C; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
    AIDS; 2010 Nov; 24(17):2651-6. PubMed ID: 20802293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
    Jaworsky D; Thompson C; Yudin MH; Bitnun A; Brophy J; Samson L; Antoniou T; Loutfy MR
    Antivir Ther; 2010; 15(4):677-80. PubMed ID: 20587860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etravirine: new drug. Multidrug-resistant HIV: another option.
    Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
    Hull MW; Montaner JS
    Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.
    Nakamura H; Miyazaki N; Hosoya N; Koga M; Odawara T; Kikuchi T; Koibuchi T; Kawana-Tachikawa A; Fujii T; Miura T; Iwamoto A
    J Infect Chemother; 2011 Feb; 17(1):105-10. PubMed ID: 20585968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
    Florence E; De Wit S; Castagna A; Ribera E; Hill A; Vanaken H; van Delft Y; Marks S
    Int J STD AIDS; 2010 Mar; 21(3):224-5. PubMed ID: 20071441
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
    Charpentier C; Fagard C; Colin C; Katlama C; Molina JM; Jacomet C; Visseaux B; Taburet AM; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
    PLoS One; 2013; 8(1):e53621. PubMed ID: 23349724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
    Caby F; Valin N; Marcelin AG; Schneider L; Andrade R; Guiguet M; Tubiana R; Canestri A; Valantin MA; Peytavin G; Pacanowski J; Morand-Joubert L; Calvez V; Girard PM; Katlama C
    Scand J Infect Dis; 2010 Jul; 42(6-7):527-32. PubMed ID: 20222846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
    Santos JR; Llibre JM; Domingo P; Imaz A; Ferrer E; Podzamczer D; Bravo I; Ribera E; Videla S; Clotet B
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):713-7. PubMed ID: 21114458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection.
    Huerta-García G; Vazquez-Rosales JG; Mata-Marín JA; Peregrino-Bejarano L; Flores-Ruiz E; Solórzano-Santos F
    Pediatr Res; 2016 Jul; 80(1):54-9. PubMed ID: 26999770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
    Do VT; Higginson RT; Fulco PP
    Am J Health Syst Pharm; 2011 Nov; 68(21):2049-54. PubMed ID: 22011983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltegravir and etravirine are active against HIV type 1 group O.
    Briz V; Garrido C; Poveda E; Morello J; Barreiro P; de Mendoza C; Soriano V
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):225-7. PubMed ID: 19239363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients.
    Briz V; Palladino C; Navarro M; Jiménez de Ory S; González-Tomé M; León J; Núñez-Cuadros E; de José M; Ramos J; Muñoz-Fernández M
    HIV Med; 2011 Aug; 12(7):442-6. PubMed ID: 21395964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
    Calin R; Paris L; Simon A; Peytavin G; Wirden M; Schneider L; Valantin MA; Tubiana R; Agher R; Katlama C
    Antivir Ther; 2012; 17(8):1601-4. PubMed ID: 22941896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.